TSE:FRX

Fennec Pharmaceuticals Stock Forecast, Price & News

C$8.22
-0.26 (-3.07 %)
(As of 06/11/2021 05:41 PM ET)
Add
Compare
Today's Range
C$8.19
C$8.83
50-Day Range
C$7.28
C$9.09
52-Week Range
C$6.29
C$14.08
Volume1,917 shs
Average Volume1,357 shs
Market CapitalizationC$213.74 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.52 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Fennec Pharmaceuticals (TSE:FRX) Frequently Asked Questions

Is Fennec Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Fennec Pharmaceuticals?

Wall Street analysts have given Fennec Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fennec Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Fennec Pharmaceuticals
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc. (TSE:FRX) issued its quarterly earnings results on Thursday, May, 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.08.
View Fennec Pharmaceuticals' earnings history
.

How has Fennec Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Fennec Pharmaceuticals' stock was trading at C$9.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FRX shares have decreased by 8.9% and is now trading at C$8.22.
View which stocks have been most impacted by COVID-19
.

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, CEO & Director (Age 45, Pay $430k)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 46, Pay $311.75k)
  • Ms. Shubh Goel, Chief Commercial Officer (Age 47, Pay $360k)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 67)
  • Mr. Alexander D. Smith M.S., Consultant

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Encanto Potash (EPO), Acadian Timber (ADN), (AD), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO (ACO.X), Accord Financial (ACD), Aurora Cannabis (ACB), Air Canada (AC) and Barrick Gold (ABX).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "FRX."

How do I buy shares of Fennec Pharmaceuticals?

Shares of FRX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FRX stock can currently be purchased for approximately C$8.22.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals has a market capitalization of C$213.74 million and generates C$170,000.00 in revenue each year.

How many employees does Fennec Pharmaceuticals have?

Fennec Pharmaceuticals employs 9 workers across the globe.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is fennecpharma.com.

Where are Fennec Pharmaceuticals' headquarters?

Fennec Pharmaceuticals is headquartered at 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company can be reached via phone at +1-919-6364530.


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.